PANDORA: Neuroprognostication Using Optic Nerve Sheath Diameter

Sponsor
TriHealth Inc. (Other)
Overall Status
Completed
CT.gov ID
NCT03195881
Collaborator
TriHealth Hatton Research Institute (Other), Jocelyn LaMar (Other), Emily Craver (Other)
25
1
31.2
0.8

Study Details

Study Description

Brief Summary

This study investigates the relationship between optic nerve sheath diameter and increased intracranial pressure and its effect on neurologic outcome in post-cardiopulmonary arrest patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Ocular ultrasound

Detailed Description

This study involves patients who have experienced either an in-hospital or out-of-hospital cardiopulmonary arrest, and who meet the 2015 American Heart Association (AHA) inclusion/exclusion criteria for targeted temperature management [i.e., they are comatose or exhibit no meaningful response to verbal commands with return of spontaneous circulation (ROSC) after cardiac arrest]. After induction of hypothermia protocol after cardiopulmonary arrest (i.e., targeted temperature management), patients will undergo ocular ultrasound at three time points.

Study Design

Study Type:
Observational
Actual Enrollment :
25 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Post Cardiac Arrest Neuroprognostication Using the Diameter of Optic Nerve Sheath Via Ocular ultRAsound
Actual Study Start Date :
May 2, 2017
Actual Primary Completion Date :
Dec 9, 2019
Actual Study Completion Date :
Dec 9, 2019

Outcome Measures

Primary Outcome Measures

  1. Optic nerve sheath diameter [0-6 hours after hypothermic protocol initiation]

    Optic nerve sheath diameter within 6 hours of hypothermic protocol initiation

Secondary Outcome Measures

  1. Optic nerve sheath diameter [10-24 hours after hypothermic protocol initiation]

    Optic nerve sheath diameter 10-24 hours after hypothermic protocol initiation

  2. Optic nerve sheath diameter [24-36 hours after hypothermic protocol initiation]

    Optic nerve sheath diameter 24-36 hours after hypothermic protocol initiation

Other Outcome Measures

  1. Modified Rankin Scale [Through day 2]

    Measure of degree of disability or dependence in daily activities on day of informed consent

  2. Modified Rankin Scale [Through 6 weeks]

    Measure of degree of disability or dependence in daily activities on day of discharge from ICU'

  3. Modified Rankin Scale [Up to 26 weeks]

    Measure of degree of disability or dependence in daily activities six months after discharge from ICU

  4. Cerebral Performance Category [Through day 2]

    Measure of neurologic outcome following cardiac arrest on day of informed consent

  5. Cerebral Performance Category [Through 6 weeks]

    Measure of neurologic outcome following cardiac arrest on day of discharge from ICU

  6. Cerebral Performance Category [Up to 26 weeks]

    Measure of neurologic outcome following cardiac arrest six months after discharge from ICU

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient ≥ 18 years of age

  • Patient has experienced either an in-hospital or out-of-hospital cardiopulmonary arrest

  • Patient is comatose or exhibits lack of meaningful response to verbal commands with return of spontaneous circulation (ROSC) after cardiopulmonary arrest

  • Patient must meet all inclusion criteria as deemed by physician and the 2015 American Heart Association standards for targeted temperature management (TTM) following cardiopulmonary arrest

Exclusion Criteria:
  • Patient < 18 years of age

  • Patient does not meet inclusion criteria for targeted temperature management (TTM)

  • Unable to obtain consent from Legal Authorized Representative (LAR)

  • Patient has a Do Not Resuscitate (DNR) order or a Do Not Intubate (DNI) order at the time of consent

  • Patient has uncontrollable bleeding

  • Patient is able to follow verbal commands

  • Patient has another medical condition creating increased ocular pressure, as deemed by physician

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bethesda North TriHealth Hospital Cincinnati Ohio United States 45242

Sponsors and Collaborators

  • TriHealth Inc.
  • TriHealth Hatton Research Institute
  • Jocelyn LaMar
  • Emily Craver

Investigators

  • Study Director: Lori Reid, MSN RN CCRC, TriHealth Hatton Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
TriHealth Inc.
ClinicalTrials.gov Identifier:
NCT03195881
Other Study ID Numbers:
  • 16-057
First Posted:
Jun 22, 2017
Last Update Posted:
Oct 19, 2020
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 19, 2020